Evidence map›Paper›PMID 32196510›Full record

ArticlePloS one2020

Natural agents inhibit colon cancer cell proliferation and alter microbial diversity in mice.

Lulu Farhana, Sarah Sarkar, Pratima Nangia-Makker, Yingjie Yu, Pramod Khosla, Edi Levi, Asfar Azmi, Adhip P N Majumdar

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Impact of curcumin on gut microbiome.World journal of experimental medicine · 2025
    Review
  6. Review
  7. Review
  8. Antioxidants (Basel, Switzerland) · 2024
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Curcumin: reclaiming the lost ground against cancer resistance.Cancer drug resistance (Alhambra, Calif.) · 2021
    Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lulu FarhanaJohn D Dingell Veterans Affairs Medical Center, Detroit, Michigan, United States of America.
Sarah SarkarJohn D Dingell Veterans Affairs Medical Center, Detroit, Michigan, United States of America.
Pratima Nangia-MakkerJohn D Dingell Veterans Affairs Medical Center, Detroit, Michigan, United States of America.
Yingjie YuJohn D Dingell Veterans Affairs Medical Center, Detroit, Michigan, United States of America.
Pramod KhoslaDepartment of Nutrition and Food Science, Wayne State University, Detroit, Michigan, United States of America.
Edi LeviJohn D Dingell Veterans Affairs Medical Center, Detroit, Michigan, United States of America.
Asfar AzmiDepartment of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan, United States of America.
Adhip P N MajumdarJohn D Dingell Veterans Affairs Medical Center, Detroit, Michigan, United States of America.ORCID 0000-0002-6413-5102
Wayne State University · USJohn D. Dingell VA Medical Center · US

Funding

Racial Disparity in Colorectal Cancer: Molecular MechanismsR21CA175916 · NCI · WAYNE STATE UNIVERSITY · PI MAJUMDAR, ADHIP P. N. · 2013 to 2014
$297k
BLRD VA I01 BX001927NCI NIH HHS R21 CA175916
6 · The paper itself

Abstract

The current study was undertaken to investigate the effect of differentially formulated polyphenolic compound Essential Turmeric Oil-Curcumin (ETO-Cur), and Tocotrienol-rich fraction (TRF) of vitamin E isomers on colorectal cancer (CRC) cells that produce aggressive tumors. Combinations of ETO-Cur and TRF were used to determine the combinatorial effects of ETO-Cur and TRF-mediated inhibition of growth of CRC cells in vitro and HCT-116 cells xenograft in SCID mice. 16S rRNA gene sequence profiling was performed to determine the outcome of gut microbial communities in mice feces between control and ETO-Cur-TRF groups. Bacterial identifications were validated by performing SYBR-based Real Time (RT) PCR. For metagenomics analysis to characterize the microbial communities, multiple software/tools were used, including Quantitative Insights into Microbial Ecology (QIIME) processing tool. We found ETO-Cur and TRF to synergize and that the combination of ETO-Cur-TRF significantly inhibited growth of HCT-116 xenografts in SCID mice. This was associated with a marked alteration in microbial communities and increased microbial OTU (operation taxonomic unit) number. The relative abundance of taxa was increased and the level of microbial diversity after 34 days of combinatorial treatment was found to be 44% higher over the control. Shifting of microbial family composition was observed in ETO-Cur-TRF treated mice as evidenced by marked reductions in Bacteroidaceae, Ruminococcaceae, Clostridiales, Firmicutes and Parabacteroids families, compared to controls. Interestingly, during the inhibition of tumor growth in ETO-Cur treated mice, probiotic Lactobacillaceae and Bifidobacteriaceae were increased by 20-fold and 6-fold, respectively. The relative abundance of anti-inflammatory Clostridium XIVa was also increased in ETO-Cur-TRF treated mice when compared with the control. Our data suggest that ETO-Cur-TRF show synergistic effects in inhibiting colorectal cancer cell proliferation in vitro and in mouse xenografts in vivo, and might induce changes in microbial diversity in mice.

Indexed as

AnimalsBiological ProductsCell ProliferationColonic NeoplasmsCurcumaCurcuminGastrointestinal MicrobiomeHCT116 CellsHumansMiceMice, SCIDPlant ExtractsTocotrienolsXenograft Model Antitumor AssaysBiological ProductsCurcuminPlant ExtractsTocotrienolsturmeric extract

Identifiers

PMID32196510
PMCPMC7083314
OpenAlexW3010683638

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.